Penobscot Investment Management Company Inc. Acquires 1490 Shares of Amgen Inc. (AMGN)

In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, October 9th. Amgen Inc now has $125.11 billion valuation. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company's stock worth $104,000 after purchasing an additional 4 shares during the last quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Finally, Nelson Roberts Investment Advisors LLC bought a new stake in shares of Amgen in the first quarter worth about $121,000. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company's stock valued at $1,403,676,000 after purchasing an additional 195,200 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Amgen by 3,664.7% in the second quarter. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Jackson Grant Investment Advisers Inc. increased its stake in Amgen by 0.6% in the 1st quarter. Cam Group Holding A sold 39,526 shares as Amgen Inc (AMGN)'s stock declined 9.68%. Integrated Wealth Management raised its stake in Amgen by 0.3% in the second quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company's stock worth $432,490,000 after acquiring an additional 551,600 shares in the last quarter. "(AMGN)" was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. Bank of Hawaii's holdings in Amgen were worth $2,799,000 at the end of the most recent quarter. Cann restated a buy rating on shares of Amgen in a report on Monday, August 28th. The Company's secondary objective is capital appreciation. The stock has "Buy" rating by UBS on Thursday, October 29. Thirteen analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. The stock now has an average rating of "Buy" and a consensus price target of $184.94.

Amgen Inc.'s ROI is valued at 13.00% relatively measuring the profitability on the investment. Papp L Roy Associate has 0.35% invested in Amgen, Inc. The stock decreased 0.49% or $0.85 during the last trading session, reaching $171.5. 852,101 shares of the company traded hands, compared to its average volume of 3,246,733. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07.

The company holds a market cap of 126.31B with a P/E of 15.56 indicating whether its share price properly reflects its performance. Amgen Inc. has a twelve month low of $138.83 and a twelve month high of $191.10.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating analysts' consensus estimates of $3.11 by $0.16. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company had revenue of $5.77 billion during the quarter, compared to analysts' expectations of $5.75 billion. After having $-0.01 EPS previously, DiaMedica Therapeutics Inc's analysts see 0.00% EPS growth.

Amgen announced that its Board of Directors has initiated a share buyback program on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. Stock repurchase plans are often an indication that the company's board believes its stock is undervalued. Stockholders of record on Wednesday, November 16th will be paid a dividend of $1.00 per share. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.48%. With the existing current ratio, Amgen more than equipped to confront its liabilities with its assets. Moreover, Saba Capital Management L.P. has 1.08% invested in the company for 1.05 million shares. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

In related news, Director Carbonnel Francois De sold 4,000 shares of the company's stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. The stock declined 0.16% or $0.08 reaching $48.68 per share. Cornercap Invest Counsel has invested 0.9% in Amgen, Inc. The Company discovers, develops, manufactures and delivers various human therapeutics.

Altre Notizie